P1-194: Hippocampal atrophy but not white-matter changes predicts the long-term cognitive response to cholinesterase inhibitors in Alzheimer's disease

2015 ◽  
Vol 11 (7S_Part_9) ◽  
pp. P423-P423
Author(s):  
Yu-Wen Cheng ◽  
Ta-Fu Chen ◽  
Ting-Wen Cheng ◽  
Ya-Mei Lai ◽  
Mau-Sun Hua ◽  
...  
2015 ◽  
Vol 27 (8) ◽  
pp. 1323-1333 ◽  
Author(s):  
Erika Droogsma ◽  
Dieneke van Asselt ◽  
Marjolein Diekhuis ◽  
Nic Veeger ◽  
Cornelis van der Hooft ◽  
...  

ABSTRACTBackground:Some guidelines recommend to discontinue treatment with cholinesterase inhibitors (ChEIs) in patients with Alzheimer's disease (AD) without an initial response to ChEI treatment. Evidence supporting this recommendation, however, is limited. This study aimed to investigate the relation between the initial cognitive response to ChEI treatment and the subsequent long-term course of cognition of AD patients.Methods:The Frisian Alzheimer's Disease Cohort study is a retrospective longitudinal study of 576 community-dwelling AD patients treated with ChEIs in a “real-life” setting at a large memory clinic. A repeated measures analysis using a marginal model (population based averaged model) was applied to investigate whether there is a difference in the subsequent long-term course of cognition (Mini-Mental State Examination (MMSE)) between initial non-responders and responders. Absence of an initial response was defined as a lower MMSE score after the first six months of treatment compared to baseline, a positive response as the same or a higher MMSE score.Results:At baseline, median age was 80 years and the median MMSE score 23. Non-responders showed a slower rate of cognitive decline in the three subsequent years than responders, with a mean annual MMSE decline of 0.9 points versus 1.2 points, respectively (p < 0.0001).Conclusions:Our results suggest that it is not appropriate to discontinue ChEI treatment solely based on the absence of an initial cognitive response.


2011 ◽  
Vol 6 (4) ◽  
pp. 228
Author(s):  
José L Molinuevo ◽  

Two effective symptomatic therapies are available for Alzheimer’s disease: the cholinesterase inhibitors (ChEIs) and memantine, an N-methyl-D-aspartate receptor antagonist. Current data demonstrate that combination therapy with memantine and a ChEI produces symptomatic benefits in all domains of AD. The benefits of combination therapy are greater than those of ChEI monotherapy, are sustained long term and appear to increase with time.


2020 ◽  
Vol 20 (12) ◽  
Author(s):  
Clive Ballard ◽  
Helen C. Kales ◽  
Constantine Lyketsos ◽  
Dag Aarsland ◽  
Byron Creese ◽  
...  

Abstract Purpose of Review To review the incidence, treatment and genetics of psychosis in people with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Recent Findings Psychosis in Alzheimer’s disease (AD) has an incidence of ~ 10% per year. There is limited evidence regarding psychological interventions. Pharmacological management has focused on atypical antipsychotics, balancing modest benefits with evidence of long-term harms. The 5HT2A inverse agonist pimavanserin appears to confer benefit in PD psychosis with initial evidence of benefit in AD. Cholinesterase inhibitors give modest benefits in DLB psychosis. The utility of muscarinic agonists, lithium, glutamatergic and noradrenergic modulators needs further study. Summary Recent work has confirmed the importance of psychosis in MCI as well as AD. The lack of evidence regarding psychological therapies is an urgent knowledge gap, but there is encouraging evidence for emerging pharmacological treatments. Genetics will provide an opportunity for precision medicine and new treatment targets.


Sign in / Sign up

Export Citation Format

Share Document